GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study
Glucagon-like peptide-1 receptor agonist as add-on therapy for six months in individuals with obesity and AID-treated T1D led to considerable weight loss and a reduction in insulin dose.
Authors
- Signe Schmidt (ORCID: https://orcid.org/0000-0002-6968-6675)
- Kirsten Nørgaard (ORCID: https://orcid.org/0000-0003-1620-8271)
- Pernille Holmager (ORCID: https://orcid.org/0000-0002-2133-5980)
- Merete B. Christensen (ORCID: https://orcid.org/0000-0002-0095-5427)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Copenhagen University Hospital (DK)
Publication Details
- Journal
- Journal of Diabetes Science and Technology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1177/19322968241289438
- Citations
- 9
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- Steno Diabetes Center Copenhagen